Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we hear about a CEO’s plans to take his company public, one day, after a hefty Series F round. Also, we see a new obesity startup launch and discuss magic bullets.
Parabilis raises $305 million, eyeing IPO
Parabilis Medicines, formerly FogPharma, has raised $305 million in a Series F round to push its lead corkscrew-shaped peptide cancer drug into late-stage trials, STAT’s Allison DeAngelis writes.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply